Medication info
Esomeprazole Magnesium Trihydrate 40 mg Tablets

Esomeprazole Magnesium Trihydrate 40 mg Tablets

Prescription medicationTablet
Ingredient · strength
Esomeprazole Magnesium Trihydrate›44.5mg / 1 tablet
Manufacturer / importer
Withus Pharm Co., Ltd.
Appearance
Pink round film-coated tablets
Packaging
28 tablets (14 tablets × 2 EA (Alu-Alu))
Approval status
Active

MFDS item code 201500108 · Approved 2015.01.12 · Insurance code 660702760

Summary

Main use
Management of reflux and Zollinger-Ellison syndrome; management of ulcers and rebleeding (including eradication therapy); relief of NSAID-related gastrointestinal symptoms
Who uses it
Adults · Children
Adult dosage
Swallow this drug with a liquid such as water. Do not chew or crush it. 1. Adults 1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, subsequent recurring symptoms are controlled by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed administration is not recommended for controlling recurring symptoms in patients at high risk of gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use. 2) Combination therapy with antibiotics for the eradication of Helicobacter pylori Administer this drug 20 mg with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning) associated with nonsteroidal anti-inflammatory drug use (nonselective or selective COX-2 inhibitors) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Clinical studies exceeding 4 weeks have not been conducted. 4) Patients requiring continuous nonsteroidal anti-inflammatory drug therapy - Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The subsequent dose should be adjusted for each patient, and treatment should continue while clinical symptoms are present. According to clinical data, most patients can be controlled with a dose of 80 ∼ 160 mg per day. Doses above 80 mg per day should be divided into two doses. 6) Maintenance therapy following intravenous induction of prevention of rebleeding from gastric or duodenal ulcers Administer 40 mg once daily for 4 weeks following intravenous induction of prevention of rebleeding from gastric or duodenal ulcers. 4. Renal impairment: No dose adjustment is necessary. Use with caution because there is limited experience in patients with severe renal impairment. 5. Hepatic impairment: No dose adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the dose of this drug should not exceed 20 mg. 6. Older adults: No dose adjustment is necessary.
Children's dosage
2. Adolescents aged 12 years and older 1) Gastroesophageal reflux disease (GERD) - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, subsequent recurring symptoms are controlled by administering 20 mg once daily. 3. Children under 12 years: There is no experience with administration of this drug to children under 12 years of age.

Ingredients

Manufacturer
Withus Pharm Co., Ltd.

Efficacy & effects

Management of reflux and Zollinger-Ellison syndrome; management of ulcers and rebleeding (including eradication therapy); relief of NSAID-related gastrointestinal symptoms

  • Gastroesophageal reflux disease
  • erosive esophagitis
  • esophagitis
  • Helicobacter pylori positive duodenal ulcers
  • peptic ulcers
  • upper gastrointestinal symptoms
  • pain
  • discomfort
  • burning sensation
  • gastric ulcers
  • duodenal ulcers
  • Zollinger-Ellison syndrome
View approved original text

This medication is used for the long-term maintenance therapy for the treatment of gastroesophageal reflux disease, particularly erosive esophagitis, and to prevent recurrence in patients with esophagitis. It also helps alleviate symptoms in gastroesophageal reflux disease without esophagitis. This medication is combined with antibiotics for the treatment and prevention of recurrence of duodenal ulcers and peptic ulcer disease associated with Helicobacter pylori infection. It is used short-term for treating upper gastrointestinal pain or discomfort related to the use of non-steroidal anti-inflammatory drugs and is effective for treating gastric ulcers and preventing ulcers in patients requiring long-term treatment. It can also be used for maintaining therapy after preventing rebleeding caused by gastric or duodenal ulcers in Zollinger-Ellison syndrome. This medication is utilized for treating various gastrointestinal diseases and improving symptoms.

Dosage and Administration

Adult dosage

Swallow this drug with a liquid such as water. Do not chew or crush it. 1. Adults 1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, subsequent recurring symptoms are controlled by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed administration is not recommended for controlling recurring symptoms in patients at high risk of gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use. 2) Combination therapy with antibiotics for the eradication of Helicobacter pylori Administer this drug 20 mg with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning) associated with nonsteroidal anti-inflammatory drug use (nonselective or selective COX-2 inhibitors) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. Clinical studies exceeding 4 weeks have not been conducted. 4) Patients requiring continuous nonsteroidal anti-inflammatory drug therapy - Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The subsequent dose should be adjusted for each patient, and treatment should continue while clinical symptoms are present. According to clinical data, most patients can be controlled with a dose of 80 ∼ 160 mg per day. Doses above 80 mg per day should be divided into two doses. 6) Maintenance therapy following intravenous induction of prevention of rebleeding from gastric or duodenal ulcers Administer 40 mg once daily for 4 weeks following intravenous induction of prevention of rebleeding from gastric or duodenal ulcers. 4. Renal impairment: No dose adjustment is necessary. Use with caution because there is limited experience in patients with severe renal impairment. 5. Hepatic impairment: No dose adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the dose of this drug should not exceed 20 mg. 6. Older adults: No dose adjustment is necessary.

Children's dosage

2. Adolescents aged 12 years and older 1) Gastroesophageal reflux disease (GERD) - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is required. · Once symptoms have resolved, subsequent recurring symptoms are controlled by administering 20 mg once daily. 3. Children under 12 years: There is no experience with administration of this drug to children under 12 years of age.

Precautions

This medication should not be administered to certain patients. It is not to be used in patients who have shown hypersensitivity to this drug or any of its components, or to benzimidazole derivatives. Additionally, patients with hypersensitivity to penicillin or macrolide antibiotics, which are used in combination for the eradication of Helicobacter pylori, should not take this medication. Patients taking specific heart-related drugs or antiviral agents, and nursing mothers should also refrain from using this medication. When taking this drug, various adverse reactions may occur. For instance, reports have included decreased blood cell counts, allergic reactions, electrolyte imbalances, mental changes, headaches, dizziness, gastrointestinal disturbances, etc. Rarely, serious skin diseases or liver dysfunction, muscle damage, and other symptoms may occur, so if unusual symptoms arise, consult a physician promptly. Regular check-ups are necessary for long-term use of this medication. Particularly for those who have been on this medication for more than one year, health status should be confirmed through blood tests or electrolyte tests. Additionally, if symptoms change or new symptoms appear while taking this medication, it is essential to consult a physician. This medication lowers stomach acid secretion, which may slightly increase the risk of bacterial infections within the stomach. Hospitalized patients or those with weakened immune systems should be cautious of symptoms of infections, such as diarrhea. Patients at risk of osteoporosis or fractures should monitor bone health when taking this medication for extended periods. Moreover, hypomagnesemia may occur with prolonged use, so it is important to periodically check magnesium levels. This medication may interact with other drugs, so if you are taking other medications, be sure to inform your healthcare provider. In particular, when taken with anticoagulants, anticonvulsants, antidepressants, and antiviral agents, it is crucial to closely observe for changes in blood concentrations or possible side effects. Data on the safety of this medication during pregnancy is limited; thus, pregnant women should carefully discuss its use with their doctors. Nursing mothers are advised not to take this medication. In case of overdose, since there is no specific antidote, symptomatic treatment based on the symptoms is necessary, and this medication is not removed through dialysis, so treatment should be followed as per medical staff's instructions. This medication should be kept out of reach of children, and transferring it to another container may lead to a decline in quality or pose risks, so caution is advised.

Side effects

Leukopenia, thrombocytopenia, agranulocytosis, pancytopenia, fever, angioedema, anaphylaxis, shock, peripheral edema, hyponatremia, hypomagnesemia, insomnia, anxiety, mental confusion, depression, aggressiveness, hallucinations, headache, dizziness, paresthesia, drowsiness, taste disturbances, blurred vision, bronchospasm, pancreatitis, abdominal pain, constipation, diarrhea, abdominal distension, nausea, vomiting, dry mouth, stomatitis, gastrointestinal candidiasis, microscopic colitis, increased liver enzymes, hepatitis, liver failure, encephalopathy, dermatitis, itching, rash, urticaria, hair loss, photosensitivity, erythema multiforme, mucocutaneous syndrome, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, drug reaction with eosinophilia and systemic symptoms, fractures, arthralgia, myalgia, muscle weakness, nephritis, gynecomastia, malaise, increased sweating, Clostridium difficile-associated diarrhea, abdominal distention, allergic reaction, back pain, chest pain, retrosternal pain, facial swelling, facial flushing, fatigue, fever, influenza-like illness, generalized edema, leg edema, lethargy, pain, stiffness, peripheral edema, flushing, hypertension, tachycardia, thyroid enlargement, irritable bowel syndrome, worsening constipation, dyspepsia, dysphagia, gastrointestinal malformation, epigastric pain, belching, esophageal disorders, frequent bowel movements, gastroenteritis, gastrointestinal bleeding, hiccups, melena, oral disorders, pharyngeal disorders, rectal disorders, gastrointestinal symptoms, increased serum gastrin, tongue disorders, tongue edema, ulcerative stomatitis, otalgia, tinnitus, anemia, hypochromic anemia, cervical lymphadenopathy, epistaxis, leukocytosis, leukopenia, thrombocytopenia, bilirubinemia, liver dysfunction, elevated ALT, elevated AST, diabetes, hyperuricemia, elevated ALP, dry mouth, vitamin B12 deficiency, weight gain, weight loss, exacerbation of arthritis, arthropathy, seizures, fibromyalgia syndrome, hernia, rheumatic polymyalgia, anorexia, apathy, increased appetite, confusion, worsening depression, hypertonicity, sensory decrease, erectile dysfunction, insomnia, migraine, worsening migraine, sleep disorders, tremor, visual disturbances, dysmenorrhea, menstrual disorders, vaginitis, worsening asthma, cough, dyspnea, laryngeal edema, pharyngitis, rhinitis, sinusitis, acne, anal itching, erythematous rash, papular rash, otitis media, dysosmia, loss of taste, taste distortion, abnormal urination, albuminuria, cystitis, dysuria, fungal infection, hematuria, urinary frequency, candidiasis, genital candidiasis, polyuria, conjunctivitis, visual disturbances, duodenitis, esophagitis, esophageal stricture, esophageal ulcer, esophageal varices, gastric ulcer, gastritis, benign polyp or nodule, Barrett's esophagus, mucosal pigmentation, hernia, systemic lupus erythematosus, cutaneous lupus erythematosus, gastric fundic polyps, hypocalcemia, hypokalemia, rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is prone to being easily affected by air or moisture, so it must be stored in a tightly sealed container. It is important to maintain the storage temperature between 1 degree and 30 degrees Celsius. Storing it this way will help maintain the effectiveness and safety of the medication.

Appearance and packaging

Appearance

Pink round film-coated tablets

Package unit

28 tablets (14 tablets × 2 EA (Alu-Alu))

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.